pd 98059 has been researched along with Anterior Optic Neuritis in 1 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maier, K | 1 |
| Rau, CR | 1 |
| Storch, MK | 1 |
| Sättler, MB | 1 |
| Demmer, I | 1 |
| Weissert, R | 1 |
| Taheri, N | 1 |
| Kuhnert, AV | 1 |
| Bähr, M | 1 |
| Diem, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT)[NCT00355095] | Phase 2 | 40 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for pd 98059 and Anterior Optic Neuritis
| Article | Year |
|---|---|
Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats.
Topics: Analysis of Variance; Animals; bcl-2-Associated X Protein; Blotting, Western; Cell Count; Cell Death | 2004 |